The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Launched by WONJU SEVERANCE CHRISTIAN HOSPITAL · May 22, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the safety of a medication called Nafamostat Mesylate for patients who are at a high risk of bleeding and are undergoing hemodialysis, a treatment for kidney failure. The study will compare Nafamostat to a commonly used blood thinner called low molecular weight heparin to see which one is safer for these patients. The trial is currently recruiting participants aged between 65 and 74 years or 36 to 159 years, regardless of gender.

To be eligible for this study, participants must have certain health conditions, such as a very low platelet count, specific bleeding issues, or recent serious bleeding in the brain. They should be receiving anticoagulant therapy or have had major surgery in the last month. However, individuals with certain conditions, like cancer or liver disease, or those who are pregnant, cannot participate. If someone joins the trial, they will help researchers learn more about how Nafamostat can be used safely in patients undergoing hemodialysis who might be at risk of bleeding.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month
• Exclusion Criteria:
• • cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)